ArticleWorld journal of gastrointestinal surgery2025
Association of serum hepatitis B surface antigen with hepatitis B virus DNA and hepatic function in patients with chronic hepatitis B.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between hepatitis B surface antigen (HBsAg) concentrations, hepatitis B virus (HBV) DNA levels, and hepatic function in individuals with chronic hepatitis B (CHB) remains incompletely characterized.
aimTo examine the association of serum HBsAg concentrations with HBV DNA levels and hepatic function parameters in patients with CHB.
methodsA total of 110 individuals with CHB admitted to Kunming Third People's Hospital between January 2023 and January 2025 were enrolled as the observation group, whereas 70 age- and sex-matched healthy individuals served as the control group. Fasting peripheral venous blood (5 mL) was collected from all participants. Serum HBsAg and HBV DNA levels (in the observation group), along with hepatic function markers, including total bilirubin (TBIL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), were measured in both groups. Pearson correlation analysis was used to assess the association between serum HBsAg levels and HBV DNA, TBIL, AST, and ALT levels in patients with CHB. Receiver operating characteristic (ROC) curve analysis was conducted to determine optimal cutoff values of HBsAg for predicting high viral load (HBV DNA ≥ 10
resultsHBsAg levels differed significantly across CHB phases: Immune tolerance (IT) phase (4.62 ± 1.51 lgIU/mL), immune clearance (IC) phase (3.84 ± 1.16 lgIU/mL), low replication (LR) phase (2.99 ± 0.66 lgIU/mL), and HBV e antigen-negative hepatitis (ENH) phase (3.40 ± 0.69 lgIU/mL). Corresponding HBV DNA levels were highest in the IT phase (7.41 ± 1.83 log copies/mL), followed by the IC phase (6.03 ± 1.92 log copies/mL), ENH phase (3.89 ± 1.23 log copies/mL), and LR phase (2.55 ± 1.00 log copies/mL). All hepatic function parameters in patients with CHB were significantly elevated compared to the healthy controls. Pearson correlation analysis showed significant positive associations between serum HBsAg levels and HBV DNA, TBIL, AST, and ALT levels. ROC analysis revealed that an HBsAg cutoff > 4.09 lgIU/mL predicted HBV DNA ≥ 10
conclusionSerum HBsAg, a noninvasive serological marker, holds significant clinical value in CHB management by aiding in the stratification of viral burden and the prediction of hepatic impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.